rs111517471 — PKP2

PKP2 Splice Variant — When the Desmosome Loses Its Molecular Rivet

The heart beats more than 2.5 billion times in a lifetime, exerting enormous mechanical stress on the junctions between adjacent cardiac muscle cells. The primary load-bearing structure at these junctions is the desmosome¹¹ desmosome
A protein complex that forms the structural glue between cardiomyocytes — analogous to a molecular rivet at a high-tension joint. Desmosomes contain several proteins including plakophilin-2 (PKP2), desmoplakin (DSP), and desmoglein-2 (DSG2), each essential for junction integrity. Plakophilin-2 (PKP2), encoded by the PKP2 gene on chromosome 12, is the single most commonly mutated gene in arrhythmogenic right ventricular cardiomyopathy (ARVC) — a condition where the right ventricular myocardium is progressively replaced by fibrofatty tissue, creating a substrate for life-threatening arrhythmias.

This variant disrupts the canonical splice donor sequence at an exon–intron boundary in PKP2. The result is aberrant mRNA splicing — either exon skipping or activation of a cryptic splice site — that eliminates functional PKP2 protein from the affected allele. With only one intact copy producing protein, desmosomal junctions in cardiomyocytes are structurally weakened, triggering a cascade of molecular changes that ultimately alter both the structural and electrical architecture of the heart.

The Mechanism

PKP2 is an armadillo-repeat protein that simultaneously anchors the desmosomal plaque to the cell membrane and recruits other junctional proteins. When a splice site is destroyed, the pre-mRNA cannot be correctly processed: either the affected exon is skipped (producing an in-frame deletion and truncated protein) or a cryptic splice site is activated (introducing a frameshift and premature stop codon). Both outcomes are subject to nonsense-mediated mRNA decay²² nonsense-mediated mRNA decay
A cellular quality-control pathway that degrades mRNAs with premature stop codons, preventing production of potentially toxic truncated proteins — at the cost of eliminating protein output from the affected allele entirely, reducing PKP2 protein levels by approximately 50%.

This haploinsufficiency triggers three distinct molecular consequences that work in concert to create the ARVC phenotype:

1. Desmosomal weakening: With half the normal PKP2, desmosomes cannot withstand the cyclic mechanical stress of cardiac contraction. Junctions progressively fail; cardiomyocytes detach and die. The heart replaces lost muscle with fibrofatty tissue — the histological hallmark of ARVC. Right ventricular free wall tissue, under the highest wall stress, is most vulnerable.

2. Electrical remodeling before structural damage: Independent of fibrosis, PKP2 loss directly impairs the cardiac sodium channel (Nav1.5) and connexin 43³³ connexin 43
The primary gap junction protein linking adjacent cardiomyocytes electrically. Its redistribution from the intercalated disk to the lateral membrane disrupts ordered electrical conduction and creates arrhythmia hotspots. Studies in haploinsufficient mice show a 27% reduction in peak sodium current and abnormal connexin 43 distribution, slowing right ventricular conduction. This electrical phenotype can precede detectable structural disease by years — explaining sudden cardiac arrest in structurally "normal" PKP2 carriers.

3. Calcium handling dysregulation: PKP2 haploinsufficiency reduces expression of key calcium-cycling proteins — SERCA2a by ~50%, calsequestrin-2 by ~38%, and ankyrin-B by ~27%. Impaired calcium cycling, compounded by exercise-induced stress, dramatically elevates arrhythmia risk even before fibrosis develops⁴⁴ even before fibrosis develops
In PKP2-haploinsufficient mice, voluntary exercise training produced 100% susceptibility to sustained ventricular arrhythmias vs 0% in trained wildtype controls.

The Evidence

PKP2 pathogenic variants are identified in 34–74% of genotype-positive ARVC cases, making them by far the most common genetic cause of the condition. Gerull et al. (Nat Genet, 2004)⁵⁵ Gerull et al. (Nat Genet, 2004) identified PKP2 mutations in 27% of 120 unrelated ARVC individuals, establishing PKP2 as a common cause of ARVC and documenting that heterozygous loss-of-function mutations produce the disease through haploinsufficiency.

Lubinski et al. (J Appl Genet, 2021)⁶⁶ Lubinski et al. (J Appl Genet, 2021) followed 56 Polish ARVC patients with detailed genotyping. PKP2 variants (present in 50% of the cohort, including two splice variants) correlated with significantly better clinical outcomes — 11% death or transplant rate vs 39% in non-PKP2 ARVC (p=0.03), younger age at diagnosis (32 vs 41 years), higher preserved LVEF, and less biventricular involvement. PKP2-ARVC is predominantly right-sided, in contrast to DSP-ACM where left ventricular fibrosis predominates.

The key caveat is penetrance: a UK Biobank analysis of 200,643 participants found PKP2 truncating variants in approximately 1 in 1,000 individuals, but only 1.6% of carriers showed ARVC features. This remarkably low penetrance⁷⁷ remarkably low penetrance
Penetrance is the proportion of people with a given genotype who show the associated phenotype. At 1.6% penetrance, most PKP2 truncating variant carriers identified by population screening will not develop clinical ARVC — but they remain at elevated lifetime risk, especially with exercise exposure underscores that additional genetic and environmental modifiers — especially endurance athletic training — are required to trigger full disease expression. Atrial fibrillation is over-represented in PKP2 carriers (OR 2.11), even in those who never develop ARVC.

Cardiac MRI with late gadolinium enhancement (LGE) can detect right ventricular fibrosis before structural criteria for ARVC are met, providing an early window for risk stratification. The validated ARVC Risk Calculator (arvcrisk.com) integrates age, sex, T-wave inversions, PVC burden, syncope history, and RVEF into a 5-year arrhythmic event probability — the current standard for primary prevention ICD decisions.

Practical Actions

For gene-positive carriers, the priority is stratifying which of the ~98% who do not yet have manifest ARVC are at highest near-term risk, versus those in whom the disease is unlikely to progress for decades. The key modifiable risk factor is exercise intensity: PKP2 haploinsufficiency produces arrhythmias during intense exercise via calcium cycling disruption and connexin 43 remodeling, even before structural changes are visible. Current ESC guidelines recommend against competitive sport and intensive endurance training in carriers with any evidence of disease, pending individualized cardiology assessment.

Flecainide has shown particular efficacy in PKP2-ARVC compared with other antiarrhythmics, likely because it targets the sodium channel deficit caused by PKP2 haploinsufficiency directly. Beta-blockers remain the first-line antiarrhythmic choice for all ARVC subtypes.

Interactions

PKP2-ARVC phenotype severity is amplified by concurrent pathogenic variants in other desmosomal genes. Carrying a PKP2 splice variant alongside a pathogenic variant in DSP (rs397516919, rs397516933) or DSG2 is associated with earlier disease onset and more severe biventricular involvement — digenic inheritance shifts the disease toward a more penetrant and aggressive phenotype. Physical activity level is the strongest known environmental modifier: endurance athletes with PKP2 pathogenic variants develop ARVC at substantially higher rates and earlier ages than sedentary carriers.